References
1. Vanoli F, Mantegazza R. Ravulizumab for the treatment of myasthenia gravis. Expert Opin Biol Ther . 2023;23(3):235-241. doi:10.1080/14712598.2023.21851312. Meisel A, Annane D, Vu T, et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.J Neurol . 2023;270(8):3862-3875. doi:10.1007/s00415-023-11699-x3. Vu T, Wiendl H, Katsuno M, Reddel S, Howard Jr J. Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence. NDT . 2023;Volume 19:2639-2655. doi:10.2147/NDT.S3746944. Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol . 2017;16(12):976-986. doi:10.1016/S1474-4422(17)30369-15. Vu T, Meisel A, Mantegazza R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid . 2022;1(5). doi:10.1056/EVIDoa21000666. Muppidi S, Utsugisawa K, Benatar M, et al. Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve . 2019;60(1):14-24. doi:10.1002/mus.264477. Vinciguerra C, Bevilacqua L, Toriello A, et al. Starting eculizumab as rescue therapy in refractory myasthenic crisis. Neurol Sci . 2023;44(10):3707-3709. doi:10.1007/s10072-023-06900-y8. Uzawa A, Ozawa Y, Yasuda M, Kuwabara S. Severe worsening of myasthenic symptoms after the eculizumab discontinuation. J Neuroimmunol . 2020;349:577424. doi:10.1016/j.jneuroim.2020.5774249. Tokuyasu D, Suzuki S, Uzawa A, et al. Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis. Ann Clin Transl Neurol . 2024;11(5):1338-1346. doi:10.1002/acn3.52051